An interventional study of transcutaneous spinal direct current stimulation and Cough Skill Training in Healthy Adult, Rehabilitation Exercise and Electric Stimulation Therapy, sponsored by University of Florida. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Florida · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Cough with a site in United States — 18 open to participants now, 22 under way, 1 of them phase 3. Cough · United States.
Among the 104 studies in Cough with a site in United States, this one is the 72nd largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2026, is one of 32 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 104th registered.
429 studies on the registry are indexed under Cough; 69 are open to participants now.
Browse Cough studies →18 of the 104 studies in Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Joseph C. Wu · Sites in United States
Ages 40+
University of Montana · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–89
Hyfe Inc · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 19 · Phase 3 12 · Phase 4 9
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 80 across 321 interventional studies indexed under Cough.
Median enrollment 63 across the 86 interventional studies, 65 across the 18 observational. Of the 75 that completed or were terminated, 35 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 104 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,289 studies on the registry; 201 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 7 studies filed under Cough — fewer than ten, so there is no comparison to draw.
7 of the studies in Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
| NCT06190171Vanderbilt University Medical CenterRespiratory Strength Training in Heart Transplant Recipients | 2027-02-01 |
| NCT07531901University of MontanaEvaluating the Feasibility and Reliability of Using Handheld Nebulizers to Conduct Cough Sensitivity Testing With Citric Acid | 2027-02-01 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 104 studies in Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effects of combining cough training with low-level electrical stimulation to the neck (tsDCS) in healthy adults and adults with neurological diseases. The main questions it aims to answer are:
Study Purpose and Background People with neurodegenerative diseases frequently experience reduced cough function (hypotussia) and swallowing difficulties (dysphagia), which negatively impact quality of life and increase the risk of pneumonia, a leading cause of death in these populations. While behavioral exercises like cough training can help improve airway protection, people with these diseases often struggle to perform them with the high intensity required to trigger lasting brain and nerve adaptation (neuroplasticity).
To overcome this limitation, this pilot study investigates a novel, non-invasive combinatorial approach: pairing Cough Skill Training (CST) with transcutaneous spinal direct current stimulation (tsDCS) applied to the neck. The theory is that spinal stimulation enhances communication between the brain and muscles, optimizing the outcomes of training. Because this combined intervention has not been tested before, this initial research aims to establish its overall feasibility and compare different stimulation settings in healthy adults before future translation to clinical patient populations.
Study Design and Methods This study is an initial pilot trial utilizing a randomized crossover design involving 16 healthy adult participants aged 40 to 85 years with normal respiratory function.
Aims:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.
Behavioral: Cough Skill Training · Device: Sham stimulation
Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.
Device: transcutaneous spinal direct current stimulation · Behavioral: Cough Skill Training
Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.
Device: transcutaneous spinal direct current stimulation · Behavioral: Cough Skill Training
Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.
CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).
Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.
Completion of training tasks with simultaneous stimulation
Measured as percentage of sessions in which both interventions can be completed simultaneously.
Time frame: During training
Peak Cough Flow
The highest rate of airflow generated during a volitional cough
Time frame: Baseline, immediate post-single-treatment measurement
Acceptability of Intervention Measure (AIM)
Participants will rate favorability of treatment procedures. This scale consists of 4 items rating acceptability using a 1-5 Likert Scale, with a combined total score range of 4-20. A score of 1 represents "completely disagree," and a score of 5 represents "completely agree." Thus, a higher score reflects a more favorable experience.
Time frame: Immediate post-single-treatment measurement
Airway occlusion pressure (P0.1)
The change in air pressure at the opening of the airway (mouth and nose) in the first 100 ms of a breath. This estimates neural drive to breathe.
Time frame: Baseline vs immediate post-single-treatment
Plan to share: Yes — Participant data that underlie the results reported in this article after deidentification.
Supporting information: Study protocol
Time frame: 9 months and ending 36 months following article publication.
Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee.
Start is estimated for Dec 2026; primary completion for Sep 2027, 9 months later.
Of 79 non-industry interventional studies with no phase under Cough, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 9 months is below that.
Counting every sponsor, half of 87 studies reached it within 15 months; a quarter within 6 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.